Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Therapy Focus
Snapshot: 2026-10-21
BCMA-Targeted Therapies Active Trials in China
As of 2026-10-21, there are 27 active clinical trials investigating BCMA-Targeted Therapies for multiple myeloma across 30 provinces and 385 study centers in China. B-cell maturation antigen (BCMA) is highly expressed on malignant plasma cells with limited expression in normal tissue, making it the most established therapeutic target in multiple myeloma. It is pursued through CAR-T, bispecific antibodies and antibody-drug conjugates.
Active Trials
27
Provinces
30
Centers
385
Active Studies (27)
Population synthesized by CMDNShowing 27 published English records of 27 registry trials.
Phase IIICTR20262221
RecruitingA Phase III, Randomized Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy (Including an Anti-CD38 Antibody and Lenalidomide)
Target Population: Relapsed/refractory
Target: Trispecific antibody targeting BCMA, GPRC5D, and CD3
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, CAMS)、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center、Shanghai Fourth People's Hospital 等 222 家中心
Phase ICTR20253656
RecruitingA Phase I Clinical Study Evaluating the Safety and Pharmacokinetics of Subcutaneous Formulation of TQB2934 for Injection in Participants with Malignant Plasma Cell Neoplasms
Target Population: Relapsed/refractory
Target: Bispecific antibody targeting BCMA×CD3
Study Sites: Zhongshan Hospital, Fudan University、The Second Affiliated Hospital of Soochow University、The First Affiliated Hospital of Xi'an Jiaotong University、Nanjing Drum Tower Hospital 等 14 家中心
Phase INCT06644118
RecruitingAn Early Exploratory Clinical Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Dual-target CAR-T cell therapy targeting GPRC5D and BCMA
Study Sites: Beijing Gobroad Hospital
Phase ITM20260016
RecruitingA Phase I Study of In Vivo CAR-T Therapy for Advanced Malignant Tumors (Multiple Myeloma, Lymphoma, Leukemia, Solid Tumors)
Target Population: Relapsed/refractory
Target: In situ (in vivo) CAR-T cell therapy targeting multiple targets including BCMA/GPRC5D/DLL3/FcRH5
Study Sites: Cancer Hospital, Chinese Academy of Medical Sciences
Phase IIICTR20233883
RecruitingAn Open-Label, Two-Arm, Multicenter, Randomized, Phase III Study Evaluating the Efficacy and Safety of ELRANATAMAB (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone in Study Participants with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible or Deferred Transplant
Target Population: Newly diagnosed/Relapsed/refractory
Target: BCMA × CD3 bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center 等 17 家中心
Phase I/IIaCTR20233309
RecruitingA Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Characteristics of KQ-2003 CAR-T Cells in Patients with Relapsed/Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Autologous BCMA/CD19 dual-targeting CAR-T
Study Sites: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital of Nanchang University、Peking University First Hospital、Henan Cancer Hospital 等 10 家中心
Phase IICTR20230238
RecruitingA Phase II, Open-label, Single-arm, Multicenter Clinical Study Evaluating the Efficacy and Safety of BCMA-targeted Chimeric Antigen Receptor T-cell Injection (CART-BCMA) in Patients with Relapsed/Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: BCMA-targeted CAR-T cell therapy
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Beijing Jishuitan Hospital、Affiliated Hospital of Hebei University 等 25 家中心
Phase ICTR20241358
RecruitingA First-in-Human (FIH), Open-Label, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Humanized GPRC5D-BCMA-CD3 Trispecific Antibody SIM0500 in Participants with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: GPRC5D × BCMA × CD3 trispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences)、Sun Yat-sen University Cancer Center、The First Affiliated Hospital, Zhejiang University School of Medicine、Beijing Chaoyang Hospital, Capital Medical University 等 7 家中心
Phase ICTR20243438
RecruitingA Phase I Clinical Study of CBG002 CAR-T Cell Injection in Patients with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: BCMA-targeting CAR-T cell therapy
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Sun Yat-sen University Cancer Center
Phase I
RecruitingA Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of CR-2011 in Relapsed/Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: In vivo chimeric antigen receptor T-cell (CAR-T) therapy targeting BCMA (based on mRNA-LNP technology)
Study Sites: Cancer Hospital Chinese Academy of Medical Sciences
Phase ICTR20241570
RecruitingA Multicenter, Open-label, Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Antitumor Efficacy of YKST02 in the Treatment of Relapsed/Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: BCMA × CD3 bispecific antibody
Study Sites: Beijing Chaoyang Hospital, Capital Medical University、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center、Harbin Medical University Cancer Hospital 等 13 家中心
Phase IIICTR20241434
RecruitingA Phase III, Randomized Study Comparing Teclistamab in Combination With Subcutaneous (SC) Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With SC Daratumumab and Lenalidomide (Tal-DR) Versus SC Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Not Eligible or Not Planned for Autologous Stem Cell Transplantation as Initial Therapy
Target Population: Newly diagnosed
Target: BCMA × CD3 bispecific antibody (MajestTEC-7 study)
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Renji Hospital, Shanghai Jiao Tong University School of Medicine、Henan Cancer Hospital、Sun Yat-sen University Cancer Center 等 32 家中心
Early Exploratory Clinical StudyNCT07622862
RecruitingAn Early Exploratory Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of BCMA/GPRC5D Dual-Targeted Allogeneic Universal CAR-T Cell Injection (DQ1001) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Target Population: Relapsed/refractory
Target: Allogeneic universal CAR-T targeting BCMA/GPRC5D
Study Sites: Zhongshan Hospital, Xiamen University
Phase Ib/IICTR20252876
RecruitingAn Open-Label, Multicenter Phase Ib/II Clinical Trial Evaluating the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of GR1803 Injection in Combination with an Anti-CD38 Monoclonal Antibody in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received at Least 1 Prior Line of Therapy (Including Lenalidomide and a Proteasome Inhibitor)
Target Population: Relapsed/refractory
Target: Novel bispecific antibody targeting BCMA (GR1803)
Study Sites: The First Affiliated Hospital of Xi'an Jiaotong University、Shanghai Fourth People's Hospital Affiliated to Tongji University、Xiangya Hospital Central South University
Phase ICTR20240189
RecruitingA Clinical Study of the Safety, Tolerability, and Preliminary Efficacy of SWK001 in Patients with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Autologous BCMA/CD19 dual-targeting CAR-T
Study Sites: The First Affiliated Hospital of USTC
Phase ICTR20242335
RecruitingAn Open-Label, Multicenter Phase I Clinical Study of SHR-9539 Injection Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients with Multiple Myeloma
Target Population: Multiple myeloma
Target: BCMA × CD3-targeting bispecific antibody
Study Sites: West China Hospital of Sichuan University、The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University、Jiangxi Provincial People's Hospital 等 28 家中心
Phase I/IICTR20243384
RecruitingA Phase I/II, Multicenter, Open-Label Study of IBI3003 in Participants with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Trispecific antibody targeting GPRC5D, BCMA, and CD3
Study Sites: Zhongshan Hospital, Fudan University、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital of Xi'an Jiaotong University、The Affiliated Hospital of Xuzhou Medical University 等 23 家中心
Phase I
RecruitingAn Early Exploratory Clinical Study on the Safety and Efficacy of KSVCBD Injection in the Treatment of CD19- and/or BCMA-Positive B-Cell Malignancies
Target Population: Relapsed/refractory
Target: CD19, BCMA dual-target in vivo CAR-T
Study Sites: Chinese PLA General Hospital (301 Hospital)
Phase IICTR20250778
RecruitingAn Open-Label, Multicenter Phase II Clinical Study Evaluating the Efficacy and Safety of F182112 in Combination with Different Dosing Regimens for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Recombinant Humanized Anti-BCMA/CD3 Bispecific Antibody for Injection
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital of Bengbu Medical University、The First Affiliated Hospital of Chongqing Medical University、Gansu Provincial Hospital 等 44 家中心
Phase IIICTR20260453
RecruitingA Multicenter, Open-label, Randomized Phase III Clinical Trial Comparing the Efficacy and Safety of GR1803 Injection Versus Daratumumab + Pomalidomide + Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received 1-3 Prior Lines of Therapy (Including Lenalidomide and a Proteasome Inhibitor)
Target Population: Relapsed/refractory
Target: BCMA-targeting bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、Henan Cancer Hospital、Shengjing Hospital of China Medical University 等 67 家中心
Phase I/IICTR20240206
RecruitingA Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MBS314 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Trispecific antibody targeting BCMA, GPRC5D, and CD3
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Beijing Chaoyang Hospital, Capital Medical University、Sun Yat-sen University Cancer Center、Shandong Cancer Hospital 等 11 家中心
Phase IICTR20261752
RecruitingA Multicenter, Open-Label Phase II Study Evaluating QLS4131 for Injection in Combination Therapy for the Treatment of Malignant Plasma Cell Neoplasms
Target Population: Multiple myeloma
Target: Trispecific antibody targeting BCMA, CD3, and GPRC5D
Study Sites: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital、Heze Municipal Hospital 等 39 家中心
Phase IIICTR20262035
RecruitingA Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Study of IBI3003 Versus Investigator's Choice of Regimen (DPd or PVd) on the Efficacy and Safety in Participants with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: GPRC5D/BCMA/CD3 trispecific antibody
Study Sites: Zhongshan Hospital, Fudan University、The First Affiliated Hospital, Zhejiang University School of Medicine、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The Affiliated Hospital of Xuzhou Medical University 等 45 家中心
Phase Ib/IICTR20221467
RecruitingA Phase Ib/II Clinical Study of CBM.BCMA Chimeric Antigen Receptor T-cell Injection (C-CAR088) in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Autologous anti-BCMA CAR-T
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin Institute of Hematology)
Phase IIICTR20242452
RecruitingA Phase III, Multicenter, Randomized, Open-Label Study Comparing Etentamig with Available Standard of Care Therapies in Participants with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
Target Population: Relapsed/refractory
Target: BCMA × CD3 bispecific T-cell engager (BiTE)
Study Sites: The First Affiliated Hospital of Nanchang University、Shanghai Tongji Hospital、Sun Yat-sen University Cancer Center、Henan Cancer Hospital 等 19 家中心
Phase IIICTR20221556
RecruitingA Phase III, Multicenter, Open-label, Randomized Study Evaluating the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 8)
Target Population: Relapsed/refractory
Target: Antibody-drug conjugate (ADC) targeting BCMA
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Sun Yat-sen University Cancer Center、Shengjing Hospital of China Medical University、Peking University Third Hospital 等 11 家中心
Phase ICTR20260125
RecruitingA Phase I, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HL17 in Participants with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Recombinant anti-BCMA and CD3 bispecific antibody injection
Study Sites: PKU Healthcare Luzhong Hospital